Screener
ImmunityBio, Inc. IBRX EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 7:37 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001326110-26-000059
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Total other expense, net | (562,997) | (65,471) |
| Loss before income taxes and noncontrolling interest | (632,788) | (129,900) |
| Income tax (expense) benefit | (9) | 234 |
| Net loss | (632,797) | (129,666) |
| Net loss attributable to noncontrolling interests, net of tax | (15) | (20) |
| Net loss attributable to ImmunityBio common stockholders | $(632,782) | $(129,646) |
| Net loss per ImmunityBio common share – basic and diluted | $(0.62) | $(0.15) |
| Weighted-average number of common shares used in computing net loss per share – basic and diluted | 1,026,874 | 853,162 |
ITEM 1. FINANCIAL STATEMENTS.
FAQ
- What is ImmunityBio, Inc.'s EPS (diluted)?
- ImmunityBio, Inc. (IBRX) reported EPS (diluted) of -$0.62 in Q1 2026.
- How has ImmunityBio, Inc.'s EPS (diluted) changed year-over-year?
- ImmunityBio, Inc.'s EPS (diluted) decreased by 313.3% year-over-year, from -$0.15 to -$0.62.
- What is the long-term trend for ImmunityBio, Inc.'s EPS (diluted)?
- Over 4 years (2021 to 2025), ImmunityBio, Inc.'s EPS (diluted) has grown at a -19.2% compound annual growth rate (CAGR), from -$0.89 to -$0.38.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about ImmunityBio, Inc.'s eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude